Follow up on Osimertinib for Advanced non–small-cell lung cancer
As a follow up to the AURA3 study previously published in The New England Journal of Medicine, which found osimertinib to be more effective than combination platinum-based chemotherapy in patients with T790M-positive non–small-cell lung cancer (N Engl J Med. 2016 December. doi: 10.1056/NEJMoa1612674), this study on “Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The AURA3 Trial” finds osimertinib to substantially improve patient-reported symptoms, functioning, health status, and quality of life (J Clin Oncol. 2018 May 7:JCO2017772293. doi: 10.1200/JCO.2017.77.2293. [Epub ahead of print]).
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Tony Mok, Chairman of Our Department of Clinical Oncology. Prof Mok’s research focuses on biomarker and molecular targeted therapy in lung cancer. He is the co-founder of the Lung Cancer Research Group, and has led multiple multinational studies leading to the establishment of the global standard on personalized medicine for lung cancer.
Read the full article: http://ascopubs.org/doi/abs/10.1200/JCO.2017.77.2293
More on our research: https://research.med.cuhk.edu.hk/